# Retatrutide vs Semaglutide: What Is the Difference?

Retatrutide and semaglutide are both incretin-receptor peptides studied in relation to body weight and glucose regulation, but semaglutide acts at one receptor and retatrutide at three. This guide explains what that difference means, what the published research covers, and where each one stands with regulators in Australia. Supplied for in vitro research purposes only.

- Source: https://www.australianresearchpeptides.au/articles/retatrutide-vs-semaglutide
- Reading time: 6 minute read
- Published: 2026-08-24
- Updated: 2026-09-02
- Publisher: Australian Research Peptides

---

## What Is the Difference Between Retatrutide and Semaglutide?

The difference is how many receptors each one acts on. Semaglutide acts at a single receptor, the GLP-1 receptor. Retatrutide acts at three at once — GIP, GLP-1 and glucagon. That is the whole of the distinction, and everything else follows from it.

One switch versus three.

Semaglutide is a single receptor agonist. Retatrutide is a triple agonist. They are not stronger and weaker versions of the same molecule — they are aimed at different numbers of targets.

## What Does Acting on Three Receptors Actually Mean?

A receptor is a docking point on the surface of a cell. When a peptide binds one, it starts a chain of events inside that cell and nothing happens at the receptors it does not bind.

Semaglutide is built to bind the GLP-1 receptor and is an acylated analogue of human GLP-1 — a modified copy of a signalling molecule the body already makes. Retatrutide binds the GIP and glucagon receptors as well, so three separate signalling routes are engaged by one molecule instead of one.

The three receptors are not variations on a theme; they belong to different signalling systems and are studied for different things. [The receptor targets guide](https://www.australianresearchpeptides.au/articles/glp-1-gip-glucagon-receptor-targets) takes each of the three in turn.

## Which One Has More Published Research Behind It?

Semaglutide has the longer published record and retatrutide has the more recent one. Semaglutide’s design was described in 2015 and it has been studied continuously since; retatrutide was first described in 2022 and has moved quickly through trial phases in the years since.

Both are unusually well documented for compounds sold as research material. That is worth saying plainly, because most peptides listed on this site or any other cannot claim a comparable body of placebo-controlled work. The references at the foot of this page are the primary sources for both.

### The Limits Are Real on Both Sides

A strong evidence base is not the same as a complete one. None of the published work on either compound used research-grade material of the kind sold here, and no published study on retatrutide has yet run beyond two years.

### Has Retatrutide Been Compared Directly With Semaglutide?

No completed head-to-head trial of retatrutide against semaglutide has been published. Every comparison available today, including this page, sets results from separate trials beside each other — and that is a weaker kind of evidence than it looks.

Separate trials enrol different people, run for different lengths of time, use different designs and analyse their results under different rules. Placing two headline percentages side by side does not show that one compound caused a bigger effect than the other. It shows what each trial reported about its own participants.

The practical rule for reading any comparison of these two: check whether the number in front of you came from one trial that contained both compounds. If it did not, it is a cross-trial comparison, and it cannot rank them.

_What kind of source each type of claim about these compounds comes from, and what that source can support_

| Kind of source | What it can support |
| --- | --- |
| Peer-reviewed randomised trial | A result in the population that trial enrolled, judged against its own control group |
| Registered study with no posted results | That the study exists, its design and its size — nothing about its outcome |
| Conference presentation | An early account of a result, usually before full peer review |
| Company topline announcement | What the sponsor chose to state, on the sponsor’s timing. Not peer review, and not a registry posting |
| Product or catalogue fact | What is supplied, at what nominal strength, and what its batch document reports — never a clinical outcome |

For which retatrutide results currently sit in which of those categories, the [trial tracker](https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record) lists every completed phase 2 and phase 3 record with its registry and publication state shown separately. That page is maintained so this one does not have to carry a second, competing set of numbers.

## Are Retatrutide and Semaglutide Approved in Australia?

Neither vial listed on this site is an approved medicine, and the two compounds sit in different places for different reasons.

**Retatrutide has no regulatory approval anywhere in the world.** It remains investigational. No launch date has been published and nobody can honestly supply one — a regulator must still receive a full dossier, review it and decide, and refusal is possible at that point.

**Semaglutide is a different case, and the distinction matters more than it first appears.** Semaglutide does exist in Australia as a registered prescription medicine sold under brand names. That approved product is a regulated pharmaceutical, made, tested and released to pharmaceutical standards, and dispensed by a pharmacist against a prescription. It is not what is listed here. The semaglutide on this site is research-grade material supplied for in vitro laboratory work, and the fact that a licensed medicine shares its name does not make the two the same product.

A shared name is not a shared product.

Any supplier who points at an approved medicine to describe research material is describing something they are not selling.

## How Do the Vial Strengths Compare?

Retatrutide is listed in three vial strengths and semaglutide in one, so retatrutide is the only one of the two where vial size is itself a decision. Each product page shows its own strengths and price.

Where a compound comes in several sizes the larger vial costs more in total and less per milligram, which is worth working out before comparing anything. [The vial size guide](https://www.australianresearchpeptides.au/articles/choosing-a-vial-size) sets out the per-milligram figures for every multi-strength compound in the catalogue, and explains why the lowest figure is not automatically the right buy.

## Which One Suits a Research Protocol?

It depends on whether the question being asked is about one signalling route or several. A protocol isolating GLP-1 receptor activity has a reason to prefer a single agonist, because anything observed cannot have come from the other two receptors. A protocol looking at combined incretin signalling has a reason to prefer the triple agonist, for the same reason in reverse.

Neither is a better compound than the other in the abstract. They answer different questions, and the one that matches the question is the right one.

Both are listed under [Metabolic Research](https://www.australianresearchpeptides.au/category/metabolic-research), where the strengths and research contexts of each sit side by side.

In vitro research purposes only.

Both compounds on this page are supplied as freeze-dried powder for in vitro laboratory research. They are not medicines, not for human or veterinary use, and nothing above is a dosing instruction or a recommendation to administer anything.

Australian Research Peptides carries both compounds compared here, retatrutide in 10 mg, 20 mg and 30 mg vials and semaglutide in 10 mg — both in stock, and each carrying a published certificate, with every order posted from Sydney to any Australian address. Prices are set out separately in [what retatrutide costs in Australia](https://www.australianresearchpeptides.au/articles/retatrutide-price-australia), which compares the three strengths per vial and per milligram.

## References

1. [Coskun T, Urva S, Roell WC, et al. Cell Metabolism 2022;34(9):1234-1247 (PMID 35985340)](https://europepmc.org/article/MED/35985340)
2. [Jastreboff AM, Kaplan LM, Frias JP, et al. New England Journal of Medicine 2023;389(6):514-526 (PMID 37366315)](https://pubmed.ncbi.nlm.nih.gov/37366315/)
3. [Rosenstock J, Frias J, Jastreboff AM, et al. The Lancet 2023;402:529-544 (PMID 37385280)](https://pubmed.ncbi.nlm.nih.gov/37385280/)
4. [ClinicalTrials.gov — LY3437943 trial registry records](https://clinicaltrials.gov/search?intr=LY3437943)
5. [Lau J, Bloch P, Schäffer L, et al. Journal of Medicinal Chemistry 2015;58(18):7370-7380 (PMID 26308095)](https://pubmed.ncbi.nlm.nih.gov/26308095/)
6. [Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism 2018;27(4):740-756 (PMID 29617641)](https://pubmed.ncbi.nlm.nih.gov/29617641/)
7. [Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021 Mar 18;384(11):989-1002 (PMID 33567185)](https://pubmed.ncbi.nlm.nih.gov/33567185/)

## Related guides

- [BPC-157 vs TB-500: What Is the Difference?](https://www.australianresearchpeptides.au/articles/bpc-157-vs-tb-500)
- [Retatrutide: What It Is and What the Trials Show](https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record)

## Related compounds

- [Retatrutide](https://www.australianresearchpeptides.au/products/retatrutide)
- [Semaglutide](https://www.australianresearchpeptides.au/products/semaglutide)

---

_Plain-text version of https://www.australianresearchpeptides.au/articles/retatrutide-vs-semaglutide. The web page is the canonical version of this article._

_All products supplied by Australian Research Peptides are for in vitro research purposes only._